VXRT.US
VXRT.US

Last Day

Biotechnology

Latest Valuation

  • Trailing PE:
  • Forward PE:
  • Price Sales TTM:
  • Price Book MRQ:
  • Enterprise Value:
  • Enterprise Value Revenue:
  • Enterprise Value Ebitda:
  • Beta:

Key Highlights

  • Shares Outstanding:
  • Market Capitalization:
  • Market Capitalization Mln:
  • EBITDA:
  • PE Ratio:
  • PEG Ratio:
  • Wall Street Target Price:
  • Book Value:
  • Dividend Share:
  • Dividend Yield:
  • Earnings Share:
  • EPS Estimate Current Year:
  • EPS Estimate Next Year:
  • EPS Estimate Next Quarter:
  • EPS Estimate Current Quarter:
  • Most Recent Quarter:
  • Profit Margin:
  • Operating Margin TTM:
  • Return On Assets TTM:
  • Return On Equity TTM:
  • Revenue TTM:
  • Revenue Per Share TTM:
  • Quarterly Revenue Growth YOY:
  • Gross Profit TTM:
  • Diluted Eps TTM:
  • Quarterly Earnings Growth YOY:

Basic Information

  • Type:
  • Name:
  • Exchange:
  • Currency Code:
  • Currency Name:
  • Currency Symbol:
  • Country Name:
  • Fiscal Year End:
  • IPO Date:
  • International Domestic:
  • Sector:
  • Industry:
  • Address:
  • Country:
  • Listings:
  • Web URL:
  • Full Time Employees:
  • Updated At:
  • Gic Sector:
  • Gic Group:
  • Gic Industry:
  • Gic SubIndustry:

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. Address: 170 Harbor Way, South San Francisco, CA, United States, 94080

2024-6-30